The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1398
ISSUE1398
September 3, 2012
Citalopram (Celexa) and QT Interval Prolongation
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Citalopram (Celexa) and QT Interval Prolongation
September 3, 2012 (Issue: 1398)
The FDA has asked the manufacturers of the selective
serotonin reuptake inhibitor (SSRI) antidepressant
citalopram (Celexa, and others) to revise the labeling
of the drug to include new warnings about the risk of
QT interval prolongation.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.